Early data from the first phase III trial of Lilly’s triple agonist show reductions in weight and HbA1c for patients with ...

Eli Lilly and Co LLY shares are down on Thursday. The company released news regarding its investigational drug, retatrutide, which has shown promising results in clinical trials. Eli Lilly Retatrutide ...

Continuing GLP-1/GIP agonist therapy prior to elective upper endoscopy increases the risk for residual gastric volume, but clear liquids the day before could mitigate the risk.

Squalene rounds out the antioxidant actives range. A lipid naturally found in human sebum, squalene provides both emollient and free-radical scavenging benefits, protecting skin against environmental ...

This randomized clinical trial found that continuing glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide ...

Alzheimer’s disease, or AD, is a terrible illness that is currently affecting 7.2 million adults in the United States. The Alzheimer’s Association predicts that without improved medical research and t ...

A new report from Lindt & Sprüngli suggests households using GLP-1 weight-loss medications are driving stronger growth in premium chocolate sales, even as some research shows overall food spending ...

A case series reports dysesthesia and allodynia in patients treated with semaglutide and tirzepatide, suggesting a possible dose related to sensory adverse effect.

The first Notice of Allowance relates to U.S. Patent Application No. 19/347,136, titled "Engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome." The ...

Division of Clinical Pharmacology, Department of Medicine, University of Western Ontario, London, Ontario, Canada, Department of Physiology and Pharmacology, University of Western Ontario, London, ...

Departments of Surgery, Bioengineering, and Chemistry, Emory University, Atlanta, Georgia 30322, and School of Textile Engineering and Chemical Engineering, Georgia Institute of Technology, Atlanta, ...